Coherus Confident On Avastin This Year With Humira Goal Achieved
Filing Of Adalimumab Was Slated For Q4 2020
Having delivered on a goal to file its Humira biosimilar with the FDA by the end of last year, Coherus BioSciences is now focused on getting its in-licensed bevacizumab product filing over the line, as it scans the market for further growth opportunities.
You may also be interested in...
A further FDA approval for a biosimilar to Humira could be on the cards, after Coherus revealed the agency’s goal date for its CHS-1420 adalimumab application.
Coherus BioSciences, a leader and innovator in the nascent US biosimilars space, has announced plans to ditch a key biosimilar opportunity and limit overall investment, in order to direct resources to immuno-oncology.
Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.